MYXR.L Regulatory News (MYXR)

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

16 March 2016

Appointment of Chief Financial Officer

The Company announces that Kimberly Slayton, formerly Interim Chief Financial Officer, has been appointed as Chief Financial Officer with immediate effect.

Grant of Share Option to Chief Financial Officer

On 14 March 2016 Ms. Slayton was awarded the following options over the Company's common shares of US$0.025 each ("Common Shares") under the MYCELX Omnibus Performance Incentive Plan ("Plan"):

Ms. Slayton holds no Common Shares in the issued capital of the Company.

Grant of Share Option to Chief Business Development Officer

The Company further announces that Mark Mixon, Chief Business Development Officer, was granted an option on 14 March 2016 under the Plan over 65,000 Common Shares. The grant to Mr. Mixon was as follows:

In addition, following this transaction, Mr. Mixon continues to be interested in 10,000 Common Shares, representing 0.05 per cent of the present issued capital of the Company, which he holds as a custodian.

Following this award, Connie Mixon, Chief Executive Officer and spouse of Mr. Mixon is interested in an aggregate (including the interests of Mr. Mixon) of 991,210 Common Shares, representing 5.28 per cent of the present issued capital of the Company, and in options over an aggregate (including the interests of Mr. Mixon) of 428,221 Common Shares, representing 2.28 per cent of the present issued capital of the Company.

The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

The above grants formed part of wider grants of 370,000 options to employees across the Company, on the same date, representing 1.97% of the current issued share capital.

The share options granted on 14 March 2016 will vest as to 50% on 31 December 2016 and 50% on 31 December 2017, and must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.

*Based on the mid-market closing price of the Company's Common Shares at 11 March 2016, and the closing US/£ exchange rate at that date.

For further information please contact:

MYCELX Technologies Corporation

Connie Mixon, CEO

Kimberly Slayton, CFO

Tel: +1 888 306 6843

Bell Pottinger

Nick Lambert

Henry Lerwill Tel: +44 20 3772 2500